DBVT - DBV Technologies S.A.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
9.73
-0.20 (-2.01%)
As of 9:56AM EST. Market open.
Stock chart is not supported by your current browser
Previous close9.93
Open9.64
Bid9.59 x 800
Ask9.65 x 1000
Day's range9.54 - 9.73
52-week range6.63 - 13.49
Volume117,626
Avg. volume454,372
Market cap1.064B
Beta (5Y monthly)1.41
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
Press releases
  • Business Wire

    Cohen Milstein Sellers & Toll PLLC Announces Investigation of DBV Technologies S.A.

    Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.

  • Business Wire

    Cohen Milstein Announces Investigation of DBV Technologies S.A.

    Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more